Simcere Received IND Approval for Two Immuno-oncology Bi-specific Antibodies from NMPA
Tsinghua University and Simcere Announce the Establishment of Joint Research Center for Innovative Drug Discovery
PHASE II/III CLINICAL TRIAL OF SIMCERE’S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
PHASE III CLINICAL STUDY OF SANBEXIN SUBLINGUAL TABLETS ACHIEVED EXPECTED EFFICACY ENDPOINTS
Giving Thanks Before Thanksgiving - Simcere Donates 5 million Yuan to Jiangsu Charity Federation
Trilaciclib RWS data featured at 2022 CSCO Annual Meeting: synergistic innovation enabled Chinese lung cancer patients to have preemptive access to international new drugs
Simcere and Idorsia enter into a licensing agreement for daridorexant in China
Simcere Doses First Patient in US Phase 1 Oncology Trial of its First-in-class TNFR2 Inhibitor, SIM0235
Simcere Receives IND Approval in the US for Bi-functional Fusion Protein, SIM0237 ——the Second US IND Approval This Year
Envafolimab Recommended by Two New CSCO Guidelines for Gynecological Tumors